Adacel vaccine—the first tetanus, diphtheria, and acellular pertussis booster vaccine for people aged 11 through 64 years
Strong immune response in both adolescents and adults that demonstrates pertussis protection
• Designed specifically to protect adolescents and adults from pertussis
• Can be used concomitantly with hepatitis B or influenza vaccines1
• Safety profile comparable to Td vaccine in both adolescents and adults
• Tetanus and diphtheria immunogenicity similar to the standard of care
MMWR May 30, 2008, Prevention of Pertussis, Tetanus, and Diphtheria Among Pregnant and Postpartum Women and Their Infants)
MMWR December 15, 2006 Adult recommendations for routine use of combined tetanus, diphtheria and acellular pertussis (Tdap) vaccines
MMWR February 23, 2006 with adolescent recommendations for routine use of Combined Tetanus, Diphtheria and Pertussis (Tdap)
Gustafsson Reprint - A Controlled Trial of a Two-Component Acellular, a Five-Component Acellular, and a Whole Cell Pertussis Vaccine
Adacel vaccine is indicated for active booster immunization for the prevention of tetanus, diphtheria, and pertussis as a single dose in persons 11 through 64 years of age.
The most common local and systemic adverse reactions to Adacel vaccine include injection site pain, erythema, and swelling; headache, body ache, tiredness, and fever. Other adverse reactions may occur. Adacel vaccine is contraindicated in persons with known systemic hypersensitivity to any component of the vaccine or a life-threatening reaction after previous administration of the vaccine or a vaccine containing the same substances. Because of uncertainty as to which component of the vaccine may be responsible, no further vaccination with the diphtheria, tetanus, or pertussis components found in Adacel vaccine should be carried out. Vaccination with Adacel vaccine may not protect all individuals.
Before administering Adacel vaccine, please see full Prescribing Information.
Reference: 1. ADACEL Vaccine full Prescribing Information, January 2006.